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T
he cell has a number of quality 
control mechanisms to ensure 
defective proteins get trashed. Most 
defects are detected and dealt with at the 
point of production to ensure that only qual-
ity proteins are released for use. But pro-
teins can also become defective once they’re 
at the job site. They 
can even be made to 
look bad by cowork-
ers that want them 
destroyed, as Gard-
ner discovered when 
studying sterol bio-
synthesis during his 
Ph.D. (1–3).
One of the most 
important job sites in 
the cell, where a pro-
tein’s performance 
must be tightly regulated, is the nucleus. 
Rather surprisingly, however, no one had 
thought to look there for protein disposal 
mechanisms. So while studying as a post-
doc at the Fred Hutchinson Cancer Research 
Center in Seattle, Gardner examined the 
fate of defective nuclear proteins (4).
Gardner has now started his own labora-
tory at the University of Washington, where 
he continues to sift through nuclear pro-
tein trash, to fi  nd out about disposal mech-
anisms and how these mechanisms might 
fail in some diseases.
SUNSHINE AND SCIENCE
Was there a deﬁ  ning moment when you 
thought, I want to be a scientist?
I don’t know if there was one defi  ning 
moment. As a kid growing up in rural Penn-
sylvania, I was always outdoors, either 
going fi  shing or capturing bugs and worms 
and butterfl  ies. I think at that point I had 
decided I really loved ecology and was actu-
ally planning to pursue a career in ecology.
What changed your mind?
While I was studying biology at Cornell, I 
took a biochemistry class and became 
really fascinated by the idea of how mole-
cules bring about all the important things 
that cells do. That really started to drive 
me toward wanting to understand the intri-
cate  internal mechanisms of life rather 
than the interactions of organisms in a 
larger environment.
I had taken some ecology courses and 
certainly loved the fi  eld trips! But I think 
I’m more of a gearhead in that I like to 
know how things work.
What inﬂ  uenced your decision to do 
your Ph.D. in San Diego—was it the 
lab or the location?
I picked the location fi  rst because Cornell, 
at the time, was going through a very 
harsh winter. The pipes in my apartment 
actually froze. I remember I was also 
thinking of coming to the University of 
Washington. I had fl  own in and inter-
viewed with the biochemistry depart-
ment and was very excited about it. But 
then I went home and went through two 
weeks of a terrible blizzard. When I fl  ew 
to San Diego for the interview, it was 70 
degrees and sunny. I said to myself, 
“You know what? I think I could spend 
fi  ve years in a warm climate.”
I did also pick UCSD because it had a 
very broad biology department. I didn’t 
know what I wanted to study when I left 
Cornell, so I wanted the opportunity to 
rotate in a lot of different labs.
You opted to work on yeast in Randy 
Hampton’s Lab. What is it you like 
about yeast?
There’s a couple of reasons I chose to 
focus on yeast. I like its simplicity—yeast 
is just a single cell, but it has to do most of 
the things that a metazoan cell does. Also, 
at the time, the yeast genome had just 
been sequenced. I realized that there was 
this powerful information sitting out there 
that would make yeast a great tool to 
study very important processes.
Randy was actually trying to under-
stand how sterols were regulated, which is 
important for understanding heart disease, 
and I thought, “Wow, wouldn’t it be great 
to take this simple system, yeast, and see 
if we could fi  gure out mechanisms that 
might apply to humans?”
In fact, many of the things that I dis-
covered during that time have now borne 
fruit, as people have started to look at 
them in mammalian systems.
What was your project in Randy’s lab?
I was working on the rate-limiting step in 
the sterol biosynthetic pathway—the deg-
radation of HMG-CoA reductase, which 
is the main target for the statin drugs.
The major discovery that I made was 
that the molecular signals that promote the 
degradation do so by somehow altering the 
structure of HMG-CoA reductase’s trans-
membrane domain such that it mimics a 
misfolded protein. This then allows it to 
be targeted by the ER quality control 
machinery for degradation.
The interesting thing is that the ER 
degradation pathway normally picks up 
proteins that misfold as they are made, but 
HMG-CoA reductase was being made to 
mimic a misfolded protein, in a regulated 
way, after having been functional.
SETTLED IN SEATTLE
For your postdoc you moved to Seattle. 
Had you had enough of the sunshine 
by then?
The funny thing is, having grown up on the 
East Coast, I love changeable weather. San 
Diego is sunny all the time, so Seattle seemed 
like a great town. It rains in Seattle, but actu-
ally the quantity is only about the same as 
you get in Philadelphia, about 40 inches a 
year. It’s just spread out over more days. It’s 
like London, where it’s misty all the time.
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Ah, yes, I can see why you love it.
[Laughs.] Also, the winter temperatures 
are quite mild, which is perfect for me. 
I don’t ever want to see snow again unless 
I go to the mountains.
You turned your attention to nuclear 
protein quality control. Why?
Realizing how important quality control 
degradation is in the cell, it started to sur-
prise me that very little was known about 
how protein homeostasis was maintained 
in the nucleus. And that was surprising 
because, if you think about it, the nucleus 
is one of the most important organelles, 
where every critical function is driven by 
proteins.
Most people were studying degradation 
in the cytoplasm and the ER because these 
are protein-folding compartments, where 
you anticipate you’re going to need to have 
quality control systems around to handle 
mistakes that happen during translation or 
folding. The nucleus isn’t involved in pro-
tein synthesis, so perhaps we didn’t really 
expect it to be in the nucleus.
So why would the nucleus need its own 
degradation pathway?
Certainly, most quality control happens at 
the production level. But you can imagine 
that a protein might be made correctly, 
shipped into the nucleus, and is happily 
going about its business, when all of a 
sudden it’s denatured by heat or reactive 
oxygen species. And once it’s in the 
nucleus, the cytoplasmic degradation 
systems can’t access it anymore.
In many of the neurodegenerative 
diseases that are associated with protein 
aggregation, the aggregates form in the 
nucleus, causing nuclear toxicity. This got 
me really interested. I thought, “Do these 
diseases show nuclear aggregation because 
the nucleus doesn’t have degradation 
systems? Or does it have degradation sys-
tems, and they’re simply failing?”
What did you ﬁ  nd?
From the ER studies in yeast, I had realized 
that most temperature-sensitive mutant 
proteins are degraded by quality control 
pathways in the ER. But from reading the 
literature, I discovered that a nucleus-
specifi  c protein called San1 suppressed a 
number of nuclear temperature-sensitive 
mutant proteins.
San1 had been discovered back in ’89 
in Jasper Rine’s lab, but people thought, 
“Well, maybe it’s just a negative regulator 
of the normal nuclear proteins.” But I 
thought, maybe San1 doesn’t regulate the 
normal versions of these proteins, but 
instead it’s actually degrading the mutant 
versions of these proteins because they 
are misfolded.
We found that San1 is a ubiquitin ligase 
and indeed it is degrading the nuclear 
temperature-sensitive proteins—the mu-
tant forms, not the wild-type forms. And, 
if we take San1 out of the nucleus, its 
substrates become stable, fi  tting the def-
inition for a nuclear 
quality control system.
We’re now charac-
terizing San1’s function, 
and our studies suggest 
that San1 does protect 
the nucleus from some 
very toxic, aggregation-
prone proteins.
Another thing that 
came out of that study 
is that we realized that 
there were some tem-
perature-sensitive proteins that weren’t 
completely stabilized in the absence of 
San1. So there’s at least one other degra-
dation pathway in the nucleus that func-
tions in quality control.
Is there any evidence for faulty nuclear 
protein disposal in the neurodegenerative 
diseases that are characterized by 
nuclear inclusions?
There was a recent report about a protein 
called PML-IV that has been shown to 
colocalize with the polyglutamine aggre-
gates that form in Huntington’s Disease.
PML bodies are thought to be sites of 
protein destruction in the nucleus. It’s 
known that the proteasomes are localized 
to PML bodies, and the PML proteins 
themselves are ubiquitin ligases. Interest-
ingly enough, if you take the human 
PML-IV sequence and search for a match 
in the yeast database, the fi  rst homologue 
that comes out is San1.
An interesting thing about the human 
aggregation diseases is that they all devel-
op later in life. So what we think is going 
on is that, when you’re young, your bur-
den of aberrant proteins in the nucleus is 
relatively low. But, as you get older, you 
produce more and more misfolded and 
damaged proteins. Eventually, a barrier is 
crossed after which the degradation sys-
tems can’t cope, and the mutant proteins 
accumulate and aggregate and cause  all 
sorts of problems in the nucleus.
Any idea how the other nuclear 
degradation pathways you mentioned 
might work?
We think that one of the other pathways 
is proteasome independent and that it 
could involve something called piece-
meal autophagy of the nucleus. This is a 
phenomenon that David Goldfarb’s lab 
recently discovered. They showed that 
there’s a route from the nucleus to the 
vacuole in yeast.
We’d now like to see if any of the 
misfolded proteins that we are studying in 
the nucleus are targeted to this autophagy 
pathway. It’s pretty exciting. This year is 
going to be a very big year for us, I think. 
We’re poised to answer some very deep 
questions in the quality control fi  eld in 
general and in trying to understand how 
the nucleus defends itself against these 
very bad, abnormal proteins.
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With San1 (top), the nucleus (blue surrounded with red) is kept 
free of aggregating mutant protein (green).